Expression cassettes for expressing genes containing overlapping open reading frames in insect cells and uses thereof - Patents.com

Expression cassettes with intron-alternative splicing in insect cells address the yield and stoichiometric challenges of rAAV production, enabling flexible and efficient large-scale production of recombinant adeno-associated viruses across various serotypes.

JP7586547B2Active Publication Date: 2024-11-19JINFAN BIOMEDICAL TECH (WUHAN) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023504515
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-09-18
Filing Date
2021-09-27
Publication Date
2024-11-19
Estimated Expiration
2041-09-27

AI Technical Summary

Technical Problem

Current methods for producing recombinant adeno-associated viruses (rAAV) in mammalian and insect cells face challenges such as low yield, contamination risks, and inability to achieve precise stoichiometric ratios of VP1, VP2, and VP3 capsid proteins, limiting large-scale and serotype-specific production.

Method used

The use of expression cassettes with duplicate open reading frames and intron-alternative splicing in insect cells to regulate the expression of VP1, VP2, and VP3 proteins, allowing for precise stoichiometric ratios and flexible production of various rAAV serotypes.

Benefits of technology

Enables stable, large-scale production of rAAV with high packaging efficiency and infectious activity, accommodating different serotypes and adjusting capsid protein ratios as needed.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586547000005
    Figure 0007586547000005
  • Figure 0007586547000006
    Figure 0007586547000006
  • Figure 0007586547000007
    Figure 0007586547000007
Patent Text Reader

Abstract

The present invention, which belongs to the field of genetic engineering, discloses an expression cassette for expressing genes containing overlapping open reading frames in insect cells and its use. The expression cassette comprises a promoter operably linked from 5' to 3' to a promoter capable of driving transcription in insect cells, an artificially constructed sequence, and an overlapping open reading frame lacking only the first translation initiation codon. The artificially constructed sequence contains a natural or artificially modified intron with splicing activity in insect cells, the intron including the translation initiation codon ATG, or the intron is located between any two adjacent nucleotides of the ATG. In the present invention, a recombinant adeno-associated virus vector containing this expression cassette utilizes a designed intron sequence to regulate the relative expression of VP1, VP2, and VP3 proteins and Rep78 and Rep52 proteins through intron splicing, thereby enabling large-scale production of rAAV with high packaging efficiency and infectivity in insect cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of genetic engineering technology, and more particularly to an expression cassette for expressing genes containing overlapping open reading frames in insect cells and its use. [Background technology]

[0002] Adeno-associated virus (AAV) (also called adeno-associated virus) belongs to the Dependovirus genus of the Parvoviridae family. It is a single-stranded DNA defective virus with the simplest structure currently expressed, and requires a helper virus (usually an adenovirus) for replication. Recombinant adeno-associated virus (rAAV) is currently one of the most promising vectors in the field of gene therapy, due to its advantages of wide host range, low immunogenicity, high safety, and the ability to mediate long-term and stable expression of foreign genes in animals. Since the first recombinant adeno-associated virus (rAAV)-mediated gene therapy drug was approved, there has been an increasing demand for large-scale AAV vector production technology (Yla-Herttuala S., 2012, Mol Ther, 20: 1831-1832).

[0003] Currently, there are mainly two systems for producing rAAV. One is a conventional production system using mammalian cells (e.g., 293 cells, COS cells, HeLa cells, KB cells, etc.). The other is a production system using insect cells. In the mammalian cell production system, the yield of rAAV particles from a single cell is low and there is a high risk of contamination during culture. This limits the large-scale production and application of rAAV in mammalian cells. In the recombinant adeno-associated virus genome, the cap gene encodes the viral VP capsid protein, which contains three structural proteins, VP1, VP2 and VP3, respectively. The stoichiometric ratio of VP1, VP2 and VP3 in AAV derived from wild-type virus is about 1:1:10. Such a stoichiometric ratio is very important for obtaining recombinant AAV. In the mammalian cell culture system, three types of AAV capsid proteins (VP1, VP2 and VP3; stoichiometric ratio 1:1:10) were obtained. This relies on the alternating use of two splice acceptor sequences in mammalian introns and the use of the VP2 suboptimal start codon ACG. However, because mammalian and insect cells have different intron splicing mechanisms, the expression profile expressed in mammalian cells is not replicated in insect cells. As a result, wild-type AAV cannot be packaged into the proper capsid in insect cells.

[0004] To overcome the above problems, Urabe et al. developed a production system in insect cells. Specifically, the start codon AUG of VP1 was replaced with the suboptimal start codon ACG to construct a single polycistronic mRNA. This polycistronic mRNA can express all three types of AAV2 VP proteins without the need for splicing (Urabe et al., 2002, Hum Gene Ther, 13:1935-1943). However, there are many AAV serotypes, which are increasing day by day, and the modification method of Urabe et al. cannot be applied to all serotypes. For example, the AAV5 particles produced by Urabe et al. in a baculovirus system using ACG as the VP1 capsid protein start codon were not sufficiently infectious. In addition, the method provided in Chinese patent CN106544325A uses a different suboptimal start codon CTG to enhance the expression of VP1. Although such a design improved the infectivity of AAV5 particles, it lacked flexibility in adjusting the relative content of VP1 / VP2 / VP3. This method also lacks the flexibility required for serotype-specific sequence adjustment. In the method provided in Chinese Patent CN101522903A, an artificial intron containing a polh promoter sequence is inserted into the open reading frame of VP1, and VP1 and VP2 / VP3 are expressed by two promoters, respectively. Although this design can achieve the expression of VP1 / VP2 / VP3 in the same reading frame, this method cannot effectively regulate the relative amounts of VP1 / VP2 / VP3, and the large difference in the capsid proteins of VP1 / VP2 / VP3 in different serotypes reduces the production efficiency.

[0005] In the AAV insect cell production system, Urabe et al. constructed two independent expression cassettes of Rep78 and Rep52 and inserted them into the same baculovirus vector. Low expression of Rep78 is favorable for AAV packaging, and Rep52 uses the Polh promoter, while Rep78 uses the △IE1 promoter, which has lower initiation activity than the Polh promoter (Urabe et al., 2002, Hum Gene Ther, 13:1935-1943). However, research has found that the AAV Rep protein expression method developed by Urabe et al. has a problem in that the passage of the baculovirus vector is unstable. To solve this problem, Chinese patent CN103849629A discloses a method for producing AAV in insect cells, which replaces the translation initiation codon of the AAV Rep78 protein with ACG. Although this method achieves expression of Rep78 and Rep52 proteins in the same reading frame, it lacks the ability to regulate the relative expression of Rep78 and Rep52 proteins.

[0006] Therefore, the development of means and methods for the stable large-scale production of recombinant adeno-associated viruses in insect cells is of great importance. Summary of the Invention

[0007] In view of the deficiencies of the prior art, the present invention aims to provide an expression cassette for expressing genes containing overlapping open reading frames in insect cells and its use. In the present invention, the alternative splicing regulating effect of the intron selectively retains, deletes or forms the translation initiation codon AUG of the VP1 protein coding sequence in the process of post-transcriptional modification, thereby realizing the expression of VP proteins (VP1 / VP2 / VP3) in the cap gene overlapping open reading frame in insect cells with accurate stoichiometry. Similarly, the alternative splicing regulating effect of the intron selectively retains, deletes or forms the translation initiation codon AUG of the Rep78 protein coding sequence in the process of post-transcriptional modification, thereby realizing the expression of Rep proteins (Rep78 / Rep52) in the rep gene overlapping open reading frame in insect cells with appropriate ratio. The present invention aims to solve the problem of producing recombinant adeno-associated viruses of various serotypes with stable large-scale high packaging rate and infection activity in insect cells.

[0008] In order to achieve the above object, the present invention provides an expression cassette for expressing a gene containing an overlapping open reading frame in an insect cell, comprising: operably linked from 5' to 3', a promoter capable of driving transcription in an insect cell; Artificially constructed sequences and A duplicated open reading frame with only the first translation initiation codon deleted; The artificially constructed sequence comprises a natural or artificially modified intron having splicing activity in an insect cell, the intron comprises a translation initiation codon ATG, or the intron is located between any two adjacent nucleotides in the ATG; In the process of post-transcriptional modification, the translation initiation codon AUG in the artificially constructed sequence is retained or deleted, or a translation initiation codon AUG is formed in the artificially constructed sequence by the selective splicing action of an intron, thereby achieving the regulation of translational expression of different protein-coding genes in the overlapping open reading frames, thereby providing an expression cassette.

[0009] Preferably, the artificially constructed sequence is operably linked from 5' to 3' a 5' portion of the intron; A translation initiation codon ATG, a 3' portion of the intron; a nucleotide sequence encoding the 2A self-cleaving peptide; Includes.

[0010] Preferably, the 2A self-cleaving peptide is a T2A peptide, a P2A peptide, an E2A peptide or an F2A peptide.

[0011] Preferably, the artificially constructed sequence is operably linked from 5' to 3': the 5' portion of the first intron; A translation initiation codon ATG, the 5' portion of the second intron; a 3' portion of the intron; and within the 5' portion of the second intron there is a stop codon, and the number of nucleotides between the stop codon and the translation initiation codon ATG is a multiple of three.

[0012] Preferably, the 5'-terminal nucleotide of the intron is GTNN, and the 3'-terminal nucleotide of the intron is NNAG, where N is any one of the four nucleotides A, T, C, and G.

[0013] Preferably, the gene containing the overlapping open reading frame is the AAV cap gene or the AAV rep gene.

[0014] Preferably, the promoter is a polh promoter or a p10 promoter.

[0015] Preferably, the gene containing the overlapping open reading frame is the cap gene of AAV and the promoter is the p10 promoter.

[0016] Preferably, the gene containing the overlapping open reading frame is the AAV rep gene and the promoter is the polh promoter.

[0017] In another aspect of the invention there is provided a nucleic acid molecule comprising a first expression cassette, said first expression cassette being the expression cassette described above.

[0018] Preferably, said nucleic acid molecule further comprises a second expression cassette, said second expression cassette being said expression cassette, wherein the gene expressed in said second expression cassette is different from the gene expressed in said first expression cassette.

[0019] Preferably, said second expression cassette is in an antisense orientation relative to said first expression cassette.

[0020] Preferably, said second expression cassette is in sense orientation relative to said first expression cassette.

[0021] Preferably, the nucleic acid molecule further comprises a foreign gene and an AAV inverted terminal repeat sequence flanking both ends of the foreign gene.

[0022] Preferably, the exogenous gene is a reporter gene, and the reporter gene is at least one of a chloramphenicol acetyltransferase-encoding gene, a β-galactosidase-encoding gene, a β-glucuronidase-encoding gene, a Renilla luciferase-encoding gene, an alkaline phosphatase-encoding gene, a firefly luciferase-encoding gene, a green fluorescent protein-encoding gene, and a red fluorescent protein-encoding gene.

[0023] Preferably, the exogenous gene is a gene encoding a drug polypeptide, which is at least one of lipoprotein esterase, apolipoprotein, cytokine, interleukin, and interferon.

[0024] In another aspect of the invention, there is provided a vector comprising the expression cassette.

[0025] Preferably, the vector is an insect cell-compatible vector.

[0026] Preferably, the vector is at least one of a plasmid and a virus.

[0027] In another aspect of the invention, there is provided the use of said vector for producing a recombinant adeno-associated virus in an insect cell.

[0028] In another aspect of the present invention, there is provided a use of said vector in the in vitro production of AAV capsids, wherein the gene containing the overlapping open reading frame is the cap gene of AAV.

[0029] In another aspect of the invention, there is provided an insect cell comprising the expression cassette.

[0030] Preferably, the expression cassette is integrated into the genome of the insect cell.

[0031] Preferably, the insect cell is an Armyworm cell, an Oreochromis major cell, a Drosophila melanogaster cell or a mosquito cell.

[0032] In another aspect of the invention, there is provided a cell culture comprising said insect cells and a medium.

[0033] Preferably, the medium contains the AAV genome.

[0034] In another aspect of the invention, there is provided a recombinant adeno-associated virus particle produced by culturing said insect cells under conditions allowing the production of recombinant adeno-associated virus particles and recovering the same.

[0035] The present invention has the following beneficial effects compared to the prior art: (1) The expression cassette of the present invention can be applied to express various polypeptides (e.g., VP proteins (VP1, VP2, VP3) and Rep proteins (Rep78, Rep52) of recombinant adeno-associated virus) encoded by genes containing overlapping open reading frames in insect cells, and there is no need to modify the original translation initiation codon ATG of the VP1 protein coding sequence or Rep78 protein coding sequence in wild-type AAV. By artificially designing an intron sequence and adjusting it so that the VP proteins (VP1, VP2, VP3) or Rep proteins (Rep78, Rep52) are expressed at an appropriate ratio, stable large-scale production of recombinant adeno-associated virus in insect cells can be realized. The present invention is different from the Chinese patent CN101522903A, which inserts an insect cell intron downstream of the translation initiation codon in the VP1 protein open reading frame, inserts a promoter into the intron, and uses four promoters (two p10 and two polh promoters) to transcribe and translate VP1, VP2 / VP3, Rep78 and Rep52 proteins, respectively. The intron alternative splicing control strategy provided by the present invention is to selectively splice the transcribed mRNA by the splicing action of the intron, obtain two or more mRNAs with appropriate ratios, and translate them into VP1, VP2 / VP3, Rep78 and Rep52 proteins, respectively. The method provided by the present invention can more effectively control the stoichiometric ratio of VP1, VP2 and VP3 proteins and the relative expression of Rep78 / Rep52.

[0036] (2) In the present invention, the intron alternative splicing strategy is used to realize the production of recombinant adeno-associated virus in insect cells, and its application to various AAV serotypes makes rAAV production more flexible and broader in scope of application.

[0037] (3) In the present invention, the AAV cap gene, rep gene and ITR core expression element carrying a foreign gene are constructed in the same recombinant baculovirus vector, and the vector is used to transfect insect host cells, thereby enabling stable and high-yield production of recombinant AAV virus particles. By adjusting the intron sequence in the cap gene expression cassette, the relative expression levels of VP1 and VP2 / VP3 can be adjusted to obtain virus particles with different VP1 uptake levels, thereby adjusting the infection activity of the rAAV virus according to different demands. [Brief description of the drawings]

[0038] [Figure 1] FIG. 2 is a schematic diagram showing the regulation of expression of the cap and rep genes in the wild-type AAV of the present invention. [Diagram 2] FIG. 1 is a schematic diagram of the expression regulation of cap gene expression cassette I in Example 1 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of cap gene expression cassette I. FIG. 3 is a schematic diagram of the translation expression of VP1 protein when splicing does not occur in the intron containing the first initiation codon AUG in the process of post-transcriptional modification. FIG. 4 is a schematic diagram of the translation expression of VP2 and VP3 proteins after splicing occurs in the intron containing the first initiation codon AUG in the process of post-transcriptional modification. [Diagram 3] FIG. 1 is a schematic diagram of the expression regulation of cap gene expression cassette II in Example 3 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of cap gene expression cassette II. FIG. 3 is a schematic diagram showing that translation of VP protein is terminated midway when splicing does not occur in either the first or second intron during the process of post-transcriptional modification. FIG. 4 is a schematic diagram of the translation expression of VP1 protein after splicing occurs in the second intron during the process of post-transcriptional modification. FIG. 5 is a schematic diagram of the translation expression of VP2 and VP3 proteins after splicing occurs in the first intron during the process of post-transcriptional modification. [Figure 4]FIG. 1 is a schematic diagram of the expression regulation of the cap gene expression cassette III in Example 5 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of the cap gene expression cassette III. FIG. 3 is a schematic diagram of the translation expression of VP2 and VP3 proteins when the intron is not cleaved and removed during the post-transcriptional modification process. FIG. 4 is a schematic diagram of the translation expression of VP1 protein after the intron is cleaved and removed during the post-transcriptional modification process. [Diagram 5] FIG. 1 is a schematic diagram of expression regulation of rep gene expression cassette I in Example 2 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of rep gene expression cassette I. FIG. 3 is a schematic diagram of translation expression of Rep78 protein when splicing does not occur in the intron containing the first start codon AUG in the process of post-transcriptional modification. FIG. 4 is a schematic diagram of translation expression of Rep52 protein after splicing occurs in the intron containing the first start codon AUG in the process of post-transcriptional modification. [Figure 6] FIG. 1 is a schematic diagram of expression regulation of rep gene expression cassette II in Example 4 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of rep gene expression cassette II. FIG. 3 is a schematic diagram showing that translation of VP protein is terminated midway when splicing does not occur in either the first or second intron during the process of post-transcriptional modification. FIG. 4 is a schematic diagram of translation expression of Rep78 protein after splicing occurs in the second intron during the process of post-transcriptional modification. FIG. 5 is a schematic diagram of translation expression of Rep52 protein after splicing occurs in the first intron during the process of post-transcriptional modification. [Figure 7] FIG. 1 is a schematic diagram of the expression regulation of the rep gene expression cassette III in Example 6 of the present invention. FIG. 2 is a schematic diagram of the DNA strand of the rep gene expression cassette III. FIG. 3 is a schematic diagram of the translation expression of the Rep52 protein when no intron splicing occurs during the post-transcriptional modification process. FIG. 4 is a schematic diagram of the translation expression of the Rep78 protein after intron splicing occurs during the post-transcriptional modification process. [Figure 8]This is a Western blot detection diagram of VP protein expressed by recombinant baculovirus vectors Ac1, Ac2, Ac3, and Ac4 containing cap gene expression cassette I in Example 7 of the present invention, and recombinant baculovirus vector Ac0 prepared in the comparative example. [Figure 9] FIG. 13 is a Western Blot detection diagram of Rep protein expressed by recombinant baculovirus vector Ac5 containing rep gene expression cassette I in Example 7 of the present invention. [Figure 10] FIG. 13 is a Western blot detection diagram of VP protein expressed by recombinant baculovirus vectors Ac6 and Ac7 containing cap gene expression cassette II in Example 7 of the present invention, and recombinant baculovirus vector Ac0 prepared in the comparative example. [Figure 11] FIG. 13 is a Western Blot detection diagram of Rep protein expressed by recombinant baculovirus vector Ac8 containing rep gene expression cassette II in Example 7 of the present invention. [Figure 12] FIG. 13 is a Western Blot detection diagram of VP protein expressed by recombinant baculovirus vectors Ac9 and Ac10 containing cap gene expression cassette III in Example 7 of the present invention, and recombinant baculovirus vector Ac0 prepared in the comparative example. [Figure 13] FIG. 13 is a Western blot detection diagram of Rep protein expressed by recombinant baculovirus vector Ac11 containing rep gene expression cassette III in Example 7 of the present invention. [Figure 14] 14A, 14B and 14C are SDS-PAGE silver staining images of recombinant AAV virus particles purified after transfection of recombinant AAV bacmids CRI-0, CRI-1, CRI-2, CRI-3, CRI-4, CRI-5, CRI-6, CRI-7 and CRI-8 into host cells in Example 10 of the present invention. Three types of capsid proteins VP1 / VP2 / VP3 are shown. [Figure 15]This is a graph showing the effect of infecting 293T cells with purified recombinant AAV virus particles after transfecting host cells with recombinant AAV bacmids CRI-0, CRI-1, CRI-2, CRI-3, CRI-4, CRI-5, CRI-6, CRI-7 and CRI-8 in Example 10 of the present invention. [Figure 16] 16A, 16B and 16C are SDS-PAGE silver staining images of recombinant AAV virus particles purified after transfection of recombinant AAV bacmids CRI-9, CRI-10, CRI-11, CRI-12, CRI-13, CRI-14, CRI-15, CRI-16 and CRI-17 in Example 11 of the present invention into host cells. Three types of capsid proteins VP1 / VP2 / VP3 are shown. [Figure 17] This is a graph showing the effect of infecting 293T cells with purified recombinant AAV virus particles after transfecting host cells with recombinant AAV bacmids CRI-9, CRI-10, CRI-11, CRI-12, CRI-13, CRI-14, CRI-15, CRI-16 and CRI-17 in Example 11 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] In order to make the objectives, technical means and advantages of the present invention clearer, the present invention will be described in more detail with reference to the following figures and examples. The following examples are merely illustrative of the present invention and are not intended to limit the present invention.

[0040] Explanation of terms

[0041] As used herein, the term "operably linked" refers to polynucleotide (or polypeptide) sequences joined in a functional relationship. Two nucleotide sequences are "operably linked" when they are in a functional relationship. For example, a transcriptional regulatory sequence (e.g., a promoter) is operably linked to a gene coding sequence if it affects the transcription of the gene coding sequence.

[0042] The term "expression cassette" refers to a nucleic acid construct that operably links a coding sequence and a regulatory sequence when introduced into a host cell, resulting in transcription and / or translation of an RNA or polypeptide, respectively. An expression cassette should be understood to include a promoter for initiating transcription, a target gene open reading frame, and a transcription terminator. Usually, the promoter sequence is located upstream of the target gene and at a distance from the target gene that is suitable for expression control.

[0043] The term "open reading frame" (ORF) refers to the normal nucleotide sequence of a structural gene, which has the function of encoding a protein or polypeptide, beginning with an initiation codon and ending with a termination codon, without any stop codon between them to terminate translation. In one mRNA chain, the ribosome starts translating from the initiation codon, synthesizes and continues to elongate a polypeptide chain along the mRNA sequence, and when it hits a termination codon, the elongation reaction of the polypeptide chain is terminated.

[0044] The term "vector" refers to a nucleic acid molecule (e.g., plasmid vectors, cosmid vectors, artificial chromosomes, phage vectors and other viral vectors) designed to transfer, transfer and / or store genetic material, as well as to express the genetic material and / or to integrate the genetic material into the chromosomal DNA of a host cell. A vector is usually composed of at least three basic units (i.e., an origin of replication, a selection marker and a multiple cloning site).

[0045] The term "intron", also called intervening sequence, refers to a segment that has no coding function in a gene or mRNA molecule, and is an intervening sequence in eukaryotic cell DNA. Intron sequences are transcribed into pre-mRNA, removed by splicing, and are ultimately absent from the mature mRNA molecule. Depending on whether the splicing process is spontaneous or requires spliceosome processing, introns are divided into self-splicing introns and spliceosomal introns. Self-splicing introns are ribozymes, which are special introns that can be excised and separated from the mRNA by their own action. The intron according to the present invention is a spliceosomal intron. The removal of such introns requires the participation of the spliceosome, and both ends of the intron sequence have splice donor and splice acceptor sequences adjacent to the cleavage and recombination sites, respectively. The spliceosome is a ribonucleoprotein complex dynamically composed of small nuclear RNA (snRNA) and protein factors. The spliceosome recognizes splice sites in pre-mRNA, catalyzes the splicing reaction, completely excises introns, and recombines upstream and downstream RNA sequences.

[0046] The term "AAV serotype": since the discovery of AAV, more than 100 AAV serotypes or variants have been isolated from adenoviruses, humans or primates, and some mammals, among which the most widely used are AAV1-9. The rAAV vectors of these serotypes mainly differ in capsid proteins. Different AAV serotypes have different infection efficiencies and tissue specificities.

[0047] All known adeno-associated virus serotypes have very similar genome structures. AAV is a single-stranded DNA virus with a simple genome structure, a total length of about 4.7 kb, and as shown in Figure 1, its genome contains a rep gene expression cassette, a cap gene expression cassette, and AAV inverted terminal repeats (ITRs) located at both ends of the genome. ITRs are palindromic structures of 125 nucleotides at both ends of the genome, and can form a self-complementary inverted T-shaped hairpin structure, which is a cis element required for the initiation of DNA replication and packaging of the recombinant AAV genome into infectious viral particles. As a defective virus, AAV cannot replicate independently in the absence of a helper virus. Therefore, AAV can only be targeted and inserted into the chromosome of a host cell to become latent. In the presence of a helper virus, the increased expression of the rep gene can rescue the AAV genome integrated (introduced) into the host cell chromosome and replicate in large quantities to obtain AAV DNA, and the single-stranded rAAV genome is packaged under the action of the VP capsid protein to become infectious virus particles. The Cap gene codes for the structural VP capsid protein and contains three overlapping open reading frames, each encoding three subunits, VP1, VP2, and VP3. VP1, VP2, and VP3 contain different initiation codons, share one stop codon, and VP1 and VP2 share the VP3 sequence. The N-terminus of VP1 has one conserved phospholipase A2 sequence. This sequence is involved in the escape of the virus from the body and is very important for its infectivity. The VP2 protein is not essential for assembly or infection. The core of the VP3 protein consists of a conserved β-barrel motif, which determines the difference between different serotypes of AAV and the host cell action receptor. The exact ratio of the three proteins in wild-type AAV is 3:3:54, approximately 1:1:10. The Rep gene encodes four overlapping multifunctional proteins: Rep78, Rep68, Rep52 and Rep40. The Rep78 and Rep68 proteins are involved in the replication and integration of AAV and can bind to specific sequences in the ITRs.The Rep52 and Rep40 proteins have helicase and ATPase activities and are involved in the replication of the single-stranded genome as well as in the assembly of the virus. Regardless of whether it is mammalian or insect cells, the unspliced ​​mRNAs encoding the Rep78 and Rep52 proteins are sufficient to meet the demands of rAAV preparation.

[0048] The nucleic acid molecule in the present invention may be a DNA molecule or an RNA molecule. As known to those skilled in the art, an RNA sequence is essentially the same as or has a certain degree of sequence identity with a DNA sequence, and thymine (T) in a DNA sequence may be considered equivalent to uracil (U) in an RNA sequence.

[0049] The intron in the present invention may be a natural intron or an artificially modified intron, and has splicing activity in insect cells, but is not limited to its origin from insect cells.

[0050] The expression cassette for expressing a gene containing an overlapping open reading frame in an insect cell provided by the present invention comprises a 5' to 3' operably linked a promoter capable of driving transcription in an insect cell; Artificially constructed sequences and A duplicated open reading frame with only the first translation initiation codon deleted; Includes. The artificially constructed sequence comprises a natural or artificially modified intron having splicing activity in insect cells, the intron comprising the translation initiation codon ATG or the intron being located between any two adjacent nucleotides of the ATG. During post-transcriptional modification, the translation initiation codon AUG in the artificially constructed sequence is retained or deleted, or an AUG translation initiation codon is formed in the artificially constructed sequence, by the alternative splicing action of the intron, thereby realizing the regulation of the translation expression of different protein-coding genes in the overlapping open reading frames.

[0051] In some embodiments, by intron alternative splicing, expression cassettes containing introns can be applied for precise expression of AAV VP capsid proteins or dominant expression of Rep proteins in insect cells, where overlapping open reading frames in the cap gene encode the AAV capsid proteins VP1, VP2, and VP3, and overlapping open reading frames in the rep gene encode the Rep78 and Rep52 proteins.

[0052] In some embodiments, by intron alternative splicing, expression cassettes containing introns can be applied to express multiple simian virus 40 (SV40) VP capsid proteins in insect cells. SV40 is a double-stranded DNA virus with a 5.2 kb covalently closed circular genome, which in turn contains three capsid proteins VP1, VP2, and VP3. VP3 protein is a truncated form of VP2 protein, and VP3 and VP2 share a stop codon. The 5' portion of the VP1 coding sequence overlaps with the 3' portion of the VP2 coding sequence, but does not have the same open reading frame. In mammalian cells, the expression of these VP proteins is regulated by an intron splicing mechanism. When the expression cassette of the present invention is used to express SV40 capsid protein in insect cells, the ORF in which only the first translation initiation codon in this expression cassette is deleted is a VP protein coding sequence in which only the VP2 protein translation initiation codon ATG is deleted, and the relative expression regulation of VP2 and VP3 proteins can be achieved by the intron splicing strategy of the present invention.

[0053] In some embodiments, the gene containing the overlapping open reading frame is the AAV cap gene. The overlapping open reading frame with only the first translation initiation codon deleted is a VP protein coding sequence with only the VP1 protein translation initiation codon ATG deleted. The artificially constructed sequence is operably linked from 5' to 3'. the 5' portion of the intron; A translation initiation codon ATG, the 3' portion of the intron; a nucleotide sequence encoding the 2A self-cleaving peptide; Includes.

[0054] In the present invention, by mutating the intron splice site at the N-terminus of the wild-type AAV VP1 protein coding sequence itself, the spliceosome in the insect cell cannot recognize this splice site, and the 5' part of the intron downstream of the start codon ATG (splice donor sequence or splice acceptor sequence) and the 3' part of the intron downstream of the ATG (splice acceptor sequence or splice donor sequence) form a complete intron splice site. As shown in Figure 2, in the process of post-transcriptional modification, when the spliceosome in the insect cell recognizes the first intron splice site and catalyzes the splicing reaction, the AUG-start site at the very tip of the mRNA is removed, and when the ribosome recognizes the start codon of the VP2 protein from 5' to 3', the VP2 protein can be translated and expressed. The VP2 start codon is a suboptimal codon ACG, which causes ribosome scanning leakage, so the VP3 protein can be translated and expressed. If the intron splice site is not recognized, the AUG-initiating site is not removed, and the mRNA is translated from the first AUG, resulting in the expression of the VP1 protein. The relative expression levels of the capsid proteins VP1, VP2, and VP3 are controlled by the intron's splicing action with a certain probability. However, when the VP1 protein is translated and expressed, another sequence from the first AUG initiating codon in the mRNA to the N-terminal sequence of the VP1 protein (i.e., a part of the intron sequence) is also translated, which affects the normal expression of the VP1 protein. Therefore, the coding sequence of the 2A self-cleaving peptides is introduced into the expression cassette provided by the present invention.

[0055] The 2A self-cleaving peptide is a peptide fragment with a length of 18-22 amino acid residues, which can induce the self-cleavage of recombinant proteins containing the 2A peptide in cells. Such peptides have a sequence motif, and the effect of "cleavage" is usually caused by the inability of ribosomes to bind at the bond between the last glycine (G) and proline (P), and the C-terminus of the 2A self-cleaving peptide and the N-terminus of the VP1 protein are cleaved to obtain normal VP1 protein. The 2A peptides currently commonly used by different viruses are T2A, P2A, E2A and F2A, and their amino acid sequences are shown in SEQ ID NO: 36 to SEQ ID NO: 39, respectively. All of these four 2A peptides can be applied to the present invention. In the examples of the present invention, T2A is taken as an example.

[0056] In some embodiments, the gene containing the overlapping open reading frame is the AAV cap gene. The overlapping open reading frame with only the first translation initiation codon deleted is a VP protein coding sequence with only the VP1 protein translation initiation codon ATG deleted. The artificially constructed sequence is operably linked from 5' to 3'. the 5' portion of the first intron; A translation initiation codon ATG, the 5' portion of the second intron; the 3' portion of the intron; Includes. Within the 5' portion of the second intron there is a stop codon, which may be TAA, TAG or TGA. The number of nucleotides between the stop codon and the translation initiation codon ATG is a multiple of three.

[0057] In the present invention, by mutating the intron splice site at the N-terminus of the wild-type AAV VP1 protein coding sequence itself, the spliceosome in the insect cell cannot recognize this splice site, and the 5' part of the first intron upstream of the start codon ATG and the 3' part of the intron downstream of the ATG form a complete first intron splice site, and the 5' part of the second intron downstream of the ATG and the 3' part of the intron form a complete second intron splice site. As shown in Figure 3, in the process of post-transcriptional modification, when the spliceosome in the insect cell recognizes the first intron splice site and catalyzes the splicing reaction, the start site at the very tip of the mRNA is removed, and when the ribosome recognizes the start codon of the VP2 protein from 5' to 3', the VP2 protein can be translated and expressed. The VP2 start codon is a suboptimal codon ACG, which causes ribosome scanning leakage, so the VP3 protein can be translated and expressed. If the spliceosome in the insect cell recognizes the second intron splice site and catalyzes the splicing reaction, and the initiation site is not removed, the mRNA will be translated from the first (first) AUG, and the VP1 protein will be expressed. If the spliceosome in the insect cell does not have a splice site for splicing the first intron or a splice site for splicing the second intron, the mRNA will start translating from the first AUG and will terminate when it reaches a stop codon inside the 5' part of the second intron, i.e., translation will be prematurely terminated and will not translate the VP1, VP2, and VP3 proteins. The different probability splicing action of different introns controls the relative expression of the capsid proteins VP1, VP2, and VP3.

[0058] In some embodiments, the gene containing the overlapping open reading frame is the AAV cap gene. The overlapping open reading frame with only the first translation initiation codon deleted is a VP protein coding sequence with only the VP1 protein translation initiation codon ATG deleted. The artificially constructed sequence is operably linked from 5' to 3'. an adenine nucleotide (A), the intron, a thymine nucleotide (T) and a guanine nucleotide (G); or It contains adenine nucleotides (A), thymine nucleotides (T), the intron and guanine nucleotides (G).

[0059] In the present invention, by mutating the intron splice site at the N-terminus of the wild-type AAV VP1 protein coding sequence itself, the spliceosome in the insect cell cannot recognize this splice site, and as shown in FIG. 4 (taking the intron inserted between the AT of ATG as an example), in the process of post-transcriptional modification, the spliceosome in the insect cell recognizes the intron splice site inserted into the VP1 protein translation start codon AUG and catalyzes the splicing reaction, and when the intron is cleaved, a complete AUG translation start site is formed, and the mRNA begins to translate from the first AUG, and the VP1 protein is expressed. If the intron splice site is not recognized, the intron is not cleaved, and a complete AUG translation start site cannot be formed, and when the ribosome recognizes the start codon of the VP2 protein from 5' to 3', the VP2 protein can be translated and expressed. The VP2 start codon is a suboptimal codon ACG, which causes ribosome scanning leakage, so the VP3 protein can be translated and expressed. The introns have a certain probability of splicing, which controls the relative expression levels of the capsid proteins VP1, VP2, and VP3.

[0060] In some embodiments, the gene containing the overlapping open reading frame is the AAV rep gene, the overlapping open reading frame with only the first translation initiation codon deleted is a Rep protein coding sequence with only the Rep78 protein translation initiation codon ATG deleted, and the artificially constructed sequence is operably linked from 5' to 3'. the 5' portion of the intron; A translation initiation codon ATG, the 3' portion of the intron; a nucleotide sequence encoding the 2A self-cleaving peptide; Includes.

[0061] In the present invention, by mutating one or more possible translation initiation sites upstream of the Rep52 protein translation initiation codon in the wild-type AAV Rep78 protein coding sequence, the ribosome in the insect cell cannot recognize these sites, and the 5' part of the intron upstream of the translation initiation codon ATG and the 3' part of the intron downstream of the ATG form a complete intron splice site, and as shown in Figure 5, in the process of post-transcriptional modification, when the spliceosome in the insect cell recognizes this intron splice site and catalyzes the splicing reaction, the AUG-initiation site at the very tip of the mRNA is removed, and the ribosome recognizes the initiation codon of the Rep52 protein from 5' to 3', and the Rep52 protein can be translated and expressed. If the intron splice site is not recognized, the AUG-initiation site is not removed, and the mRNA starts to translate from the first AUG, and the 2A self-cleaving peptide has a self-shearing function, so that the Rep78 protein is cleaved from the C-terminus of the 2A self-cleaving peptide to release the Rep78 protein. The relative expression levels of Rep78 and Rep52 proteins are controlled by the splicing activity of introns with a certain probability.

[0062] In some embodiments, the gene containing the overlapping open reading frame is the AAV rep gene, the overlapping open reading frame with only the first translation initiation codon deleted is a Rep protein coding sequence with only the Rep78 protein translation initiation codon ATG deleted, and the artificially constructed sequence is operably linked from 5' to 3'. the 5' portion of the first intron; A translation initiation codon ATG, the 5' portion of the second intron; the 3' portion of the intron; Includes. Within the 5' portion of the second intron there is a stop codon, which may be TAA, TAG or TGA. The number of nucleotides between the stop codon and the translation initiation codon ATG is a multiple of three.

[0063] In the present invention, by mutating one or more possible translation initiation sites upstream of the Rep52 protein translation initiation codon in the wild-type AAV Rep78 protein coding sequence, the ribosomes in insect cells cannot recognize these sites, and the 5' part of the first intron upstream of the translation initiation codon ATG and the 3' part of the intron downstream of the ATG form a complete first intron splice site, and the 5' part of the second intron downstream of the ATG and the 3' part of the intron form a complete second intron splice site, as shown in FIG. 6. In the process of post-transcriptional modification, when the spliceosomes in insect cells recognize the first intron splice site and catalyze the splicing reaction, the AUG-initiation site at the very tip of the mRNA is removed, and when the ribosomes recognize the initiation codon of the Rep52 protein from 5' to 3', the Rep52 protein can be translated and expressed. If the spliceosome in insect cells recognizes the second intron splice site and catalyzes the splicing reaction, and the AUG-start site is not removed, the mRNA will be translated from the first AUG and the Rep78 protein will be expressed. If the spliceosome in insect cells does not have a splice site for splicing the first intron or a splice site for splicing the second intron, the mRNA will start translating from the first AUG and terminate when it reaches a stop codon inside the 5' part of the second intron, that is, translation will be terminated prematurely and will not translate Rep78 and Rep52 proteins. The different probability splicing action of different introns controls the relative expression levels of Rep78 and Rep52 proteins.

[0064] In some embodiments, the gene containing the overlapping open reading frame is the Rep gene of AAV. The overlapping open reading frame with only the first translation initiation codon deleted is a Rep protein coding sequence with only the Rep78 protein translation initiation codon ATG deleted. The artificially constructed sequence is operably linked from 5' to 3'. an adenine nucleotide (A), the intron, a thymine nucleotide (T) and a guanine nucleotide (G); or It contains adenine nucleotides (A), thymine nucleotides (T), the intron and guanine nucleotides (G).

[0065] In the present invention, by mutating one or more possible translation initiation sites upstream of the Rep52 protein translation initiation codon in the wild-type AAV Rep78 protein coding sequence, the ribosomes in insect cells cannot recognize these sites, and as shown in FIG. 7 (the figure takes an example in which an intron is inserted between the AT of ATG), during the process of post-transcriptional modification, the spliceosomes in insect cells recognize the intron splice site inserted into the Rep78 protein translation initiation codon AUG and catalyze a splicing reaction, and when the intron is cleaved, a complete AUG translation initiation site is formed, and the mRNA starts to translate from the first AUG, and the Rep78 protein is expressed. If the intron splice site is not recognized and the intron is not cleaved, a complete AUG translation initiation site cannot be formed, and the ribosomes recognize the initiation codon of the Rep52 protein from 5' to 3', and the Rep52 protein can be translated and expressed. The relative expression levels of the Rep78 protein and the Rep52 protein are controlled by the intron having a certain probability of splicing action.

[0066] In some embodiments, preferably, the 5'-end nucleotide of the intron is GTNN, and the 3'-end nucleotide of the intron is NNAG. Here, N represents any one of four types of nucleotides, A, T, C, and G. More specifically, the 5'-end nucleotides of the first intron and the 5'-end nucleotides of the second intron are both GTNN, and the 3'-end nucleotide of the intron is NNAG. In this way, the VP1, VP2, and VP3 proteins can be adjusted to be translated and expressed in a ratio closer to the stoichiometric ratio. This is advantageous for packaging into a suitable capsid. Similarly, the translational expression level of the Rep78 protein is lower than that of the Rep52 protein, which is advantageous for a relatively high vector yield.

[0067] In some embodiments, the intron nucleotide sequence is the sequence shown in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 20 or SEQ ID NO: 21. As known to those skilled in the art, variations of the intron sequence can be applied to the technical means of the present invention. In some structures, sequences having identity to the intron nucleotide sequences of the present invention can be used. Examples include sequences whose 5' end has at least 40%, 50%, 60%, 70%, 80% or 90% identity to the sequence GTAAGTATCG, whose 5' end has at least 40%, 50%, 60%, 70%, 80% or 90% identity to the sequence GTAAGTATTC, whose 3' end has at least 40%, 50%, 60%, 70%, 80% or 90% identity to the sequence CCTTTTCCTTTTTTTTTCAG, whose 3' end has at least 40%, 50%, 60%, 70%, 80% or 90% identity to the sequence AAACATTATTTATTTTGCAG, or whose 3' end has 40%, 50%, 60%, 70%, 80% or 90% identity to the sequence CATTTGGATATTGTTTCAG.

[0068] In some embodiments, the VP capsid protein encoded by the cap gene can be a capsid protein of any AAV serotype, such as AAV serotype 2, AAV serotype 5, AAV serotype 8, AAV serotype 9, etc. The intron sequences and splicing strategies of the present invention can be applied to precisely express VP capsid proteins of multiple conventional AAV serotypes.

[0069] In some embodiments, the promoter capable of driving transcription of the cap and rep genes in insect cells may be a polh promoter or a p10 promoter. Preferably, the cap gene expression cassette uses the p10 promoter and the rep gene expression cassette uses the polh promoter.

[0070] The present invention further provides a nucleic acid molecule comprising said cap gene expression cassette and / or rep gene expression cassette. The nucleic acid may comprise expression cassettes arranged in tandem, i.e., in the same polarity or antisense orientation. Thus, the cap gene expression cassette may be in the antisense orientation relative to the rep gene expression cassette, or in the sense orientation relative to the rep gene expression cassette.

[0071] The present invention further provides a recombinant adeno-associated virus vector, preferably a vector compatible with insect cells. The vector comprises a cap gene expression cassette and a rep gene expression cassette. The cap gene expression cassette is preferably an expression cassette constructed in the present invention, and the rep gene expression cassette is preferably a gene expression cassette constructed in the present invention. As can be understood, the rAAV vector further comprises a foreign gene and an AAV inverted terminal repeat located at both ends of the foreign gene. The ITRs act on the replication and packaging of AAV and targeted integration, and help the vector form a stable circular polymer and chromatin-like structure in the host cell, so that the vector can stably exist in the host cell for a long period of time, and the foreign gene can also be continuously and stably expressed. The foreign gene may be at least one nucleotide sequence encoding a gene of interest (GOI) product. The gene product of interest may be a therapeutic gene product, specifically a polypeptide, an RNA molecule (siRNA), or other gene product. For example, it may be, but is not limited to, lipoprotein esterase, apolipoprotein, cytokine, interleukin or interferon, or a reporter protein for evaluating vector transformation and expression, for example, but is not limited to, a fluorescent protein (green fluorescent protein GFP, red fluorescent protein RFP), chloramphenicol acetyltransferase, β-galactosidase, β-glucuronidase, Renilla luciferase, firefly luciferase or alkaline phosphatase.

[0072] Meanwhile, the present invention further provides the use of the recombinant adeno-associated virus vector in the production of recombinant adeno-associated virus in insect cells. By introducing this vector into insect cells, VP1, VP2, and VP3 proteins are expressed in a precise stoichiometric ratio of 1:1:10, which allows packaging to produce recombinant adeno-associated virus with a high packaging rate. Most of the known AAV serotypes (e.g., AAV2, AAV5, AAV8, and AAV9) have excellent infectivity, and the expression levels of Rep78 and Rep52 proteins can be controlled within a reasonable range, allowing stable and large-scale production of AAV vectors in insect cells. In addition, the recombinant adeno-associated virus vector containing a cap gene expression cassette can be applied to the preparation of AAV capsids in vitro.

[0073] On the other hand, the present invention further provides an insect cell, which contains an expression cassette of the cap gene and / or the rep gene of AAV, and may further contain an expression cassette of a foreign gene, at least one of which may be integrated into the genome of the host insect cell and stably expressed, and may instantly deliver nucleic acids containing these expression cassettes to the insect cell.

[0074] In some embodiments, the insect cell may be any insect cell, such as, but not limited to, a Spodoptera frugiperda cell, a Spodoptera looper moth cell, a Drosophila melanogaster cell, or a mosquito cell, preferably a Spodoptera frugiperda cell sf9.

[0075] Meanwhile, the present invention further provides a cell culture comprising said insect cells and a medium. In some embodiments, the medium comprises an AAV genome.

[0076] On the other hand, the present invention further provides recombinant adeno-associated virus particles produced by culturing said insect cells under conditions allowing the production of recombinant adeno-associated virus particles, followed by harvesting.

[0077] The above technical solutions will be described in detail below with specific examples.

[0078] Example 1: Construction of a recombinant baculovirus vector containing an AAV serotype 9 cap gene expression cassette (1) Construction of cap gene expression cassette I As shown in FIG. 2, the cap gene expression cassette I includes, from 5' to 3', a p10 promoter, an intron, a nucleotide sequence encoding a T2A peptide, and a nucleotide sequence encoding an AAV serotype 9 VP protein lacking only the VP1 protein translation initiation codon ATG. The nucleotide sequence of the p10 promoter is shown in SEQ ID NO:1. In the cap gene expression cassette I, four types of introns are provided in this embodiment, and their nucleotide sequences are shown in SEQ ID NO:2 to SEQ ID NO:5, respectively. All of these introns include the translation initiation codon ATG. The nucleotide sequence encoding the T2A peptide is shown in SEQ ID NO:6. The nucleotide sequence encoding the AAV serotype 9 VP protein is shown in SEQ ID NO:7, and at its amino terminus, there is at least one nucleotide mutation to remove a possible cleavage site within the coding sequence. The sequences were artificially directly synthesized or amplified by overlap extension PCR and then joined to obtain constructs 9K-1, 9K-2, 9K-3, and 9K-4, respectively. Their nucleotide sequences are shown in SEQ ID NO:8 to 11, respectively.

[0079] (2) Construction of recombinant baculovirus vector The construct 9K-1 was cloned into pFastBac vector to prepare a transfer plasmid. The plasmids were transformed into DH10Bac strain, respectively, and recombinant baculovirus vector Ac1 was obtained by Tn7 transposition. Similarly, recombinant baculovirus vector Ac2 containing 9K-2, recombinant baculovirus vector Ac3 containing 9K-3, and recombinant baculovirus vector Ac4 containing 9K-4 were obtained.

[0080] Example 2: Construction of a recombinant baculovirus vector containing the AAV serotype 2 rep gene expression cassette I (1) Construction of rep gene expression cassette I As shown in FIG. 5, the rep gene expression cassette I includes, in order from 5' to 3', a polh promoter, an intron, a nucleotide sequence encoding a T2A peptide, and a nucleotide sequence encoding an AAV serotype 2 Rep protein lacking only the Rep78 protein translation initiation codon ATG. The nucleotide sequence of the polh promoter is shown in SEQ ID NO: 12. The nucleotide sequence of the intron in the rep gene expression cassette of this embodiment is shown in SEQ ID NO: 5, and this intron contains the translation initiation codon ATG. The nucleotide sequence encoding the T2A peptide is shown in SEQ ID NO: 6. The nucleotide sequence encoding the AAV serotype 2 Rep protein is shown in SEQ ID NO: 13, and there are multiple nucleotide mutations between the Rep78 translation initiation codon and the Rep52 translation initiation codon to remove a translation initiation site that may be present in this region. The above sequences were artificially directly synthesized or amplified by overlap extension PCR and then joined to obtain construct 2R-1. Their nucleotide sequences are shown in SEQ ID NO: 14, respectively.

[0081] (2) Construction of recombinant baculovirus vector A recombinant baculovirus vector Ac5 containing 2R-1 was produced in the same manner as in step (2) of Example 1.

[0082] Example 3: Construction of a recombinant baculovirus vector containing AAV serotype 9 cap gene expression cassette II (1) Construction of cap gene expression cassette II As shown in FIG. 3, the cap gene expression cassette II includes, from 5' to 3', the p10 promoter, an artificially constructed sequence, and a nucleotide sequence encoding an AAV serotype 9 VP protein with only the VP1 protein translation initiation codon ATG deleted. The nucleotide sequence of the p10 promoter is shown in SEQ ID NO: 1. In the cap gene expression cassette II, two artificially constructed sequences are provided in this embodiment, the nucleotide sequences of which are shown in SEQ ID NO: 15 and SEQ ID NO: 16, respectively, and both of these artificially constructed sequences include the translation initiation codon ATG and also include two intron splice sites. The nucleotide sequence encoding the AAV serotype 9 VP protein is shown in SEQ ID NO: 7, and at its amino terminus, there is at least one nucleotide mutation to remove a possible cleavage site within the coding sequence. The sequences were artificially directly synthesized or amplified by overlap extension PCR and then joined to obtain constructs 9K-5 and 9K-6, respectively. Their nucleotide sequences are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively.

[0083] (2) Construction of recombinant baculovirus vector In the same manner as in step (2) of Example 1, recombinant baculovirus vectors Ac6 containing 9K-5 and Ac7 containing 9K-6 were produced.

[0084] Example 4: Construction of a recombinant baculovirus vector containing the AAV serotype 2 rep gene expression cassette II (1) Construction of rep gene expression cassette II As shown in FIG. 6, the rep gene expression cassette II includes, in the order from 5' to 3', a polh promoter, an artificially constructed sequence, and a nucleotide sequence encoding an AAV serotype 2 Rep protein in which only the Rep78 protein translation initiation codon ATG is deleted. The nucleotide sequence of the polh promoter is shown in SEQ ID NO: 12. The nucleotide sequence of the artificially constructed sequence in the rep gene expression cassette II of this embodiment is shown in SEQ ID NO: 16. This artificially constructed sequence includes a translation initiation codon ATG and also includes two intron splice sites. The nucleotide sequence encoding the AAV serotype 2 Rep protein is shown in SEQ ID NO: 13, and there are multiple nucleotide mutations between the Rep78 translation initiation codon and the Rep52 translation initiation codon to remove a translation initiation site that may be present in this region. The construct 2R-2 was obtained by artificially directly synthesizing the sequence or amplifying and ligating it by overlap extension PCR. Its nucleotide sequence is shown in SEQ ID NO: 19.

[0085] (2) Construction of recombinant baculovirus vector The recombinant baculovirus vector Ac8 containing 2R-2 was obtained in the same manner as in step (2) of Example 1.

[0086] Example 5: Construction of a recombinant baculovirus vector containing the AAV serotype 9 cap gene expression cassette III (1) Construction of cap gene expression cassette III As shown in FIG. 4, the cap gene expression cassette III includes, from 5' to 3', a p10 promoter, an adenine nucleotide (A), an intron, a thymine nucleotide (T), a guanine nucleotide (G), and a nucleotide sequence encoding an AAV serotype 9 VP protein with only the VP1 protein translation initiation codon ATG deleted. The nucleotide sequence of the p10 promoter is shown in SEQ ID NO: 1. In the cap gene expression cassette III, two types of introns are provided in this embodiment, and their nucleotide sequences are shown in SEQ ID NO: 20 and SEQ ID NO: 21, respectively. The nucleotide sequence encoding an AAV serotype 9 VP protein is shown in SEQ ID NO: 7, and at its amino terminus, there is at least one nucleotide mutation to remove a possible cleavage site within the coding sequence. The sequences were artificially directly synthesized or amplified by overlap extension PCR and then joined to obtain constructs 9K-7 and 9K-8, respectively. Their nucleotide sequences are shown in SEQ ID NO: 22 and SEQ ID NO: 23, respectively.

[0087] (2) Construction of recombinant baculovirus vector In the same manner as in step (2) of Example 1, recombinant baculovirus vectors Ac9 containing 9K-7 and Ac10 containing 9K-8 were produced.

[0088] Example 6: Construction of a recombinant baculovirus vector containing the AAV serotype 2 rep gene expression cassette III (1) Construction of rep gene expression cassette III As shown in FIG. 7, the rep gene expression cassette III includes, from 5' to 3', a polh promoter, A, an intron, TG, and a nucleotide sequence encoding an AAV serotype 2 Rep protein with only the Rep78 protein translation initiation codon ATG deleted. The nucleotide sequence of the polh promoter is shown in SEQ ID NO: 12. The nucleotide sequence of the intron in the rep gene expression cassette III of this embodiment is shown in SEQ ID NO: 21. The nucleotide sequence encoding the AAV serotype 2 Rep protein is shown in SEQ ID NO: 13, and there are multiple nucleotide mutations between the Rep78 translation initiation codon and the Rep52 translation initiation codon to remove a translation initiation site that may be present in this region. The construct 2R-3 was obtained by artificially directly synthesizing the above sequences or by amplifying and ligating them by overlap extension PCR. The nucleotide sequence is shown in SEQ ID NO: 24.

[0089] (2) Construction of recombinant baculovirus vector A recombinant baculovirus vector Ac11 containing 2R-3 was produced in the same manner as in step (2) of Example 1.

[0090] Comparative Example: Construction of Recombinant Baculovirus Vector Ac0 and Rep Gene Expression Cassette (1) Construction of cap gene expression cassette In this comparative example, a cap gene expression cassette was constructed according to the method of Urabe et al. (Urabe et al., 2002, Hum Gene Ther, 13:1935-1943). The p10 promoter was used as the promoter of this cap gene expression cassette, and the cap gene in the expression cassette encoded AAV serotype 9 VP protein, and the translation initiation codon ATG of VP1 in the coding sequence was mutated to the suboptimal codon ACG. This cap gene expression cassette is numbered 9K-0, and its nucleotide sequence is shown in SEQ ID NO:25.

[0091] (2) Construction of recombinant baculovirus vector A recombinant baculovirus vector Ac0 containing 9K-0 was produced in the same manner as in step (2) of Example 1.

[0092] (3) Construction of rep gene expression cassette According to the method of Chinese patent CN103849629A, a rep gene expression cassette is constructed, and the polh promoter is used as the promoter of this rep gene expression cassette, and the rep gene in the expression cassette codes for AAV serotype 2 Rep protein, and the original translation initiation codon ATG of AAV Rep78 protein is replaced with ACG. The number of this rep gene expression cassette is 2R-0.

[0093] Example 7: Detection of expression status of VP proteins (VP1, VP2, VP3) and Rep proteins (Rep78, Rep52) The recombinant baculovirus vectors Ac0, Ac1, Ac2, Ac3, Ac4, Ac5, Ac6, Ac7, Ac8, Ac9, Ac10 and Ac11 prepared in Examples 1-6 and Comparative Example were transfected into host cell lines and cultured to obtain recombinant baculoviruses. The expression of VP proteins (VP1, VP2, VP3) and Rep proteins (Rep78, Rep52) was detected. The specific operation procedure is as follows: The recombinant baculovirus vector DNA was extracted and transfected into Sf9 insect cells to prepare the recombinant baculovirus BEV. The transfected Sf9 insect cells successfully produced BEV. The BEV replicated and proliferated in large quantities and further infected Sf9 cells, causing a significant cytopathic effect (CPE). The culture supernatant of Sf9 cells with CPE was collected. The culture supernatant contained a large amount of BEV (0th generation BEV (P0)). In addition, Sf9 cells containing a large amount of rAAV were collected. The prepared BEV-P0 was infected into suspension-cultured Sf9 cells at a multiplicity of infection (MOI = 1), and 72 hours after infection, the cell activity was reduced to 50% or less. The cell culture solution was centrifuged at 1000g for 5 min, the culture supernatant and cell precipitate were collected, and the supernatant was labeled as 1st generation BEV-P1. After subsequent expansion, the prepared BEV-P1 was infected into suspension-cultured Sf9 cells at a multiplicity of infection (MOI = 1), and 72 hours after infection, the cell activity had decreased to less than 50%. The cell culture medium was centrifuged at 1000g for 5 min, and the cell pellet was collected and subjected to Western blotting to detect the expression of VP proteins (VP1, VP2, VP3) and Rep proteins (Rep78, Rep52).

[0094] Figure 8 shows Western Blot detection of VP proteins (VP1, VP2 and VP3) of recombinant baculovirus vectors Ac1, Ac2, Ac3, Ac4 containing cap gene expression cassette I and control recombinant baculovirus vector Ac0. As can be seen from the figure, all of the above recombinant baculovirus vectors can produce VP1, VP2 and VP3 at appropriate ratios. Ac4 has higher VP1 production compared to Ac1-Ac3. Higher VP1 incorporation may cause higher infection activity. The reason for higher VP1 production is that the intron contained in Ac4 has lower splicing activity than other vectors.

[0095] 9 is a Western blot detection diagram of Rep proteins (Rep78 and Rep52) of the recombinant baculovirus vector Ac5 containing the rep gene expression cassette I. As can be seen from the figure, the recombinant baculovirus vector Ac5 can produce Rep78 and Rep52 proteins, and the expression level of Rep78 protein is lower than that of Rep52 protein.

[0096] Figure 10 shows Western Blot detection of VP proteins (VP1, VP2 and VP3) of recombinant baculovirus vectors Ac6 and Ac7 containing cap gene expression cassette II and control recombinant baculovirus vector Ac0. As can be seen from the figure, Ac0, Ac6 and Ac7 can all produce VP1, VP2 and VP3 in appropriate ratios. Ac7 has higher VP1 production compared to Ac6. Higher VP1 incorporation may cause higher infection activity. The higher VP1 production is due to the higher alternative splicing activity of the second intron splice donor and intron splice acceptor contained in Ac7.

[0097] 11 is a Western blot detection diagram of Rep proteins (Rep78 and Rep52) of the recombinant baculovirus vector Ac8 containing the rep gene expression cassette II. As can be seen from the figure, the recombinant baculovirus vector Ac8 can produce Rep78 and Rep52 proteins.

[0098] Figure 12 shows Western Blot detection of VP proteins (VP1, VP2 and VP3) of recombinant baculovirus vectors Ac9 and Ac10 containing cap gene expression cassette III and control recombinant baculovirus vector Ac0. As can be seen from the figure, Ac0, Ac9 and Ac10 can all produce VP1, VP2 and VP3 in appropriate ratios. Ac10 has higher VP1 production compared to Ac9. Higher VP1 incorporation may cause higher infection activity. The higher VP1 production is due to the higher splicing activity of the intron contained in Ac10 than Ac9.

[0099] 13 is a Western Blot detection diagram of Rep proteins (Rep78 and Rep52) of the recombinant baculovirus vector Ac11 containing the rep gene expression cassette III. As can be seen from the figure, the recombinant baculovirus vector Ac11 can properly produce Rep78 and Rep52 proteins.

[0100] Example 8: Construction of recombinant AAV bacmid for producing AAV virus in insect cells In this embodiment, the construction method of recombinant AAV bacmid for producing AAV virus in insect cells follows Example 1 described in our patent CN112553257A. The procedure is as follows: (1) A homologous recombination vector containing the AAV essential functional elements cap and rep gene expression cassette was constructed, and then the essential functional elements in this homologous recombination vector were inserted into the C-terminus of the essential gene Ac135 (116492...117391) in the baculovirus genome by Red homologous recombination in Escherichia coli to obtain a recombinant baculovirus vector (number: Bac-Cap-Rep) containing the cap and rep gene expression cassette. (2) Construction of shuttle vector containing ITR core element (ITR-GOI) The number of the ITR core element is IG-1, and its nucleotide sequence is shown in SEQ ID NO: 26. In this example, the red fluorescent protein mcherry gene expression cassette is used as the GOI in the ITR core element, that is, the mcherry expression is controlled by the miniEf1a promoter, which is convenient for detecting the activity of rAAV. The ITR and red fluorescent protein expression cassette were constructed on the shuttle vector pFastDual. (3) The shuttle vector constructed in step (2) was used to transform competent cells containing the Bac-Cap-Rep recombinant bacmid, and the ITR-GOI was inserted into the Tn7 site of the Bac-Cap-Rep recombinant bacmid by Tn7 recombination, finally obtaining a recombinant bacmid (number: Bac-Cap-Rep-ITR-GOI) of a recombinant baculovirus genome containing functional protein components and ITR core elements required for rAAV production. The nine different recombinant AAV bacmids constructed in this example all contain a cap gene expression cassette, a rep gene expression cassette and an ITR core element, as shown in Table 1.

[0101] JPEG0007586547000001.jpg82160

[0102] Example 9: Preparation of AAV recombinant baculovirus The recombinant AAV bacmids CRI-0, CRI-1, CRI-2, CRI-3, CRI-4, CRI-5, CRI-6, CRI-7 and CRI-8 prepared in Example 4 were each transfected into a host cell line and cultured to obtain AAV recombinant baculoviruses. The recombinant bacmid DNA was extracted and transfected into Sf9 insect cells to prepare recombinant baculoviruses BEV and rAAV. After transfection, the Sf9 insect cells successfully produced BEV. Further infection with BEV, which replicated and multiplied in large quantities, caused a significant cytopathic effect (CPE) in the Sf9 cells. The culture supernatant of the Sf9 cells in which CPE occurred was collected and contained a large amount of BEV (i.e., 0th generation BEV (P0)). In addition, Sf9 cells containing a large amount of rAAV were collected. The prepared BEV-P0 was infected into suspension-cultured Sf9 cells at a multiplicity of infection (MOI = 1), and 72 hours after infection, the cell activity was reduced to 50% or less. The cell culture was centrifuged at 1000g for 5 min, and the culture supernatant and cell precipitate were collected, respectively. The supernatant was labeled as 1st generation BEV-P1, and the cells were labeled as rAAV packaged with BEV-P0.

[0103] Example 10: Purification of recombinant AAV virus particles and detection of their packaging rate and virus titer According to the procedure of Example 9, the seed virus of BEV-P2 was used to infect suspension-cultured Sf9 cells at a multiplicity of infection (MOI=1) to package rAAV, and the cells were expanded until the packaging volume reached 300mL-400mL. Three days after infection, the cell activity was monitored and found to be less than 50%. The cells were centrifuged to obtain cell pellets and supernatants, respectively. The resulting cell pellets and supernatants were purified, and the cells were decomposed and dissolved by freezing and thawing three times, centrifuged at 5000 rpm for 10 min, and the supernatant was collected. Nuclease (Benzonase) was added to the supernatant, and the cells were treated in a water bath at 37°C for 60 min, followed by centrifugation at 5000 rpm for 10 min. The collected cell lysates and collected supernatants were precipitated with PEG, resuspended, and then purified by density gradient centrifugation with iodixanol (Aslanidi et al., 2009, Proc. Natl Acad. Sci. USA, 206:5059-5064). The final purified virus product was resuspended in 80 μL-190 μL of PBS, and 10 μL of the purified virus product was taken and run on an SDS-PAGE gel and silver stained.

[0104] 14A, 14B, and 14C are the detection diagrams of SDS-PAGE silver staining of the purified recombinant AAV virus after transfection of recombinant AAV bacmids CRI-0, CRI-1, CRI-2, CRI-3, CRI-4, CRI-5, CRI-6, CRI-7, and CRI-8 into host cells. As can be seen from the results, the recombinant AAV bacmids constructed in the present invention can achieve the expression of VP1, VP2, and VP3 proteins in insect cells in an appropriate ratio through the intron splicing regulation effect, which can be packaged into virus particles. Here, the virus particles of CRI-4, CRI-6, and CRI-7 have higher VP1 protein incorporation amount than CRI-3, CRI-5, and CRI-8, respectively. The reason for this phenomenon is the relatively high expression amount of VP1 protein. The relative expression amount of VP1 protein depends on the splicing efficiency of the intron. By adjusting the intron sequence and changing the intron splicing efficiency, it is possible to obtain virus particles with different VP1 incorporation amounts.

[0105] In this example, the packaging rate of the obtained rAAV virus was detected by Q-PCR. The detection of the rAAV packaging rate was performed using a pair of primers targeting the ITR sequence (Q-ITR-F: GGAACCCCTAGTGATGGAGTT and Q-ITR-R: CGGCCTCAGTGAGCGA). The detection of the rAAV infectious titer was performed by the detection method described in our patent CN112280801A. For specific operation methods, please refer to the detection method of AAV infectious titer using a plasmid described in the same patent. The detection results are shown in Table 2.

[0106] JPEG0007586547000002.jpg78159

[0107] As can be seen from Table 2 and Figure 15, the recombinant AAV bacmids CRI-1 to CRI-8 prepared in the present invention could be packaged into recombinant baculoviruses by transfection into insect cells, and the packaging rate and viral infectious titer were high, and were comparable to or higher than those of the viral particles produced by the recombinant AAV bacmid CRI-0 containing the control cap gene expression cassette. CRI-4, CRI-6 and CRI-7 had higher viral infectious titers than CRI-3, CRI-5 and CRI-8, respectively, and their VP1 incorporation amounts were also relatively high.

[0108] Example 11: Verification of intron regulatory effects of different AAV serotypes It was verified that the above intron regulation method can work in different AAV serotypes. The method of Example 1 was used to construct the cap gene expression cassette 2K-1 of AAV serotype 2, the cap gene expression cassette 5K-1 of AAV serotype 5, and the cap gene expression cassette 8K-1 of AAV serotype 8, respectively. The method of Example 3 was used to construct the cap gene expression cassette 2K-2 of AAV serotype 2, the cap gene expression cassette 5K-2 of AAV serotype 5, and the cap gene expression cassette 8K-2 of AAV serotype 8, respectively. The method of Example 5 was used to construct the cap gene expression cassette 2K-3 of AAV serotype 2, the cap gene expression cassette 5K-3 of AAV serotype 5, and the cap gene expression cassette 8K-3 of AAV serotype 8, respectively. The nucleotide sequences of the above constructs 2K-1, 2K-2, 2K-3, 5K-1, 5K-2, 5K-3, 8K-1, 8K-2, and 8K-3 are shown in SEQ ID NO:27 to SEQ ID NO:35, respectively. In this example, AAV serotype 2 was used as the rep gene expression cassette because the Rep protein of AAV serotype 2 is applicable to the preparation of various serotypes of rAAV.

[0109] In this example, nine different recombinant AAV bacmids were constructed with reference to Example 8. All of them contain a cap gene expression cassette, a rep gene expression cassette and an ITR core element. The details are shown in Table 3.

[0110] JPEG0007586547000003.jpg82164

[0111] In this example, referring to Example 9 and Example 10, the recombinant AAV bacmid was transfected into host cells, and the purified recombinant AAV virus particles were detected by SDS-PAGE silver staining. The experimental results are shown in Figures 16A, 16B, and 16C. The cell packaging rate and virus infection titer of rAAV produced by recombinant AAV bacmids of different serotypes were detected. The detection results are shown in Table 4.

[0112] JPEG0007586547000004.jpg78159

[0113] As can be seen from the results in Table 4 and Figure 17, the present invention uses intron splicing to regulate the expression of VP1, VP2 and VP3 proteins in insect cells in a relatively appropriate ratio, and can be applied to various AAV serotypes, all of which can produce rAAV virus particles on a large scale.

[0114] Those skilled in the art can understand that the above are only preferred embodiments of the present invention, and do not limit the present invention. Any modifications, equivalent replacements and improvements made within the spirit and principle of the present invention are all within the scope of protection of the present invention.

Claims

1. 1. An expression cassette for expressing genes containing overlapping open reading frames in insect cells, comprising: operably linked from 5' to 3', a promoter capable of driving transcription in an insect cell; Artificially constructed sequences and an overlapping open reading frame lacking the first translation initiation codon; The artificially constructed sequence comprises a natural or artificially modified intron having splicing activity in an insect cell, the intron comprises a translation initiation codon ATG, or the intron is located between any two adjacent nucleotides of the ATG; An expression cassette characterized in that the translation start codon AUG in the artificially constructed sequence is retained or deleted, or a translation start codon AUG is formed in the artificially constructed sequence, by the selective splicing action of an intron, thereby producing proteins of different lengths via a single overlapping open reading frame.

2. The artificially constructed sequence is operably linked from 5' to 3' a 5' portion of the intron; A translation initiation codon ATG; a 3' portion of the intron; a nucleotide sequence encoding a 2A self-cleaving peptide; The expression cassette of claim 1 , comprising:

3. 3. The expression cassette of claim 2, wherein the 2A self-cleaving peptide is a T2A peptide, a P2A peptide, an E2A peptide or an F2A peptide.

4. The artificially constructed sequence is operably linked from 5' to 3' a 5' portion of the first intron; A translation initiation codon ATG; a 5' portion of the second intron; a 3' portion of the intron shared by the first intron and the second intron; The expression cassette of claim 1, wherein the second intron has a stop codon within the 5' portion thereof, and the number of nucleotides between the stop codon and the translation start codon ATG is a multiple of 3.

5. The expression cassette of claim 1, wherein the 5'-terminal nucleotide of the intron is GTNN, the 3'-terminal nucleotide of the intron is NNAG, and N is any one of the four nucleotides A, T, C, and G.

6. The expression cassette according to claim 1 , wherein the gene containing the overlapping open reading frame is an AAV cap gene or an AAV rep gene.

7. The expression cassette according to claim 1 , wherein the promoter is a polh promoter or a p10 promoter.

8. The expression cassette of claim 7, wherein the gene containing the overlapping open reading frame is an AAV cap gene and the promoter is a p10 promoter, or the gene containing the overlapping open reading frame is an AAV rep gene and the promoter is a polh promoter.

9. A nucleic acid molecule, characterized in that it comprises an expression cassette according to any one of claims 1 to 8.

10. A nucleic acid molecule comprising a first expression cassette and a second expression cassette, The nucleic acid molecule described in claim 9, characterized in that the first expression cassette and the second expression cassette are each an expression cassette described in any one of claims 1 to 8, and the gene expressed by the second expression cassette is different from the gene expressed by the first expression cassette.

11. The nucleic acid molecule of claim 10, wherein the second expression cassette is in an antisense orientation relative to the first expression cassette, or the second expression cassette is in a sense orientation relative to the first expression cassette.

12. 10. The nucleic acid molecule of claim 9, further comprising an exogenous gene and AAV inverted terminal repeat sequences located on both ends of the exogenous gene.

13. the exogenous gene is a reporter gene, the reporter gene is at least one of a chloramphenicol acetyltransferase-encoding gene, a β-galactosidase-encoding gene, a β-glucuronidase-encoding gene, a Renilla luciferase-encoding gene, an alkaline phosphatase-encoding gene, a firefly luciferase-encoding gene, a green fluorescent protein-encoding gene, and a red fluorescent protein-encoding gene; or The nucleic acid molecule according to claim 12, wherein the exogenous gene is a gene encoding a drug polypeptide, and the drug polypeptide is at least one of lipoprotein esterase, apolipoprotein, cytokine, interleukin, and interferon.

14. A vector comprising an expression cassette according to any one of claims 1 to 8.

15. The vector according to claim 14, characterized in that the vector is an insect cell-compatible vector.

16. Use of the vector according to claim 14 for preparing a recombinant adeno-associated virus in an insect cell.

17. 15. Use of the vector according to claim 14 in the preparation of AAV capsids in vitro, comprising: The use, characterized in that the gene containing the overlapping open reading frame is an AAV cap gene.

18. An insect cell, characterized in that it contains an expression cassette according to any one of claims 1 to 8.

19. 20. The insect cell of claim 18, wherein the expression cassette is integrated into the genome of the insect cell.

Citation Information

Patent Citations

  • Engineered nucleic acid constructs encoding AAV production proteins

    CN113166731A

  • Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor

    US8945918B2